GSK picks Flagship\'s Quotient, ProFound as 1st biotech partners for $7B pact

20 Nov 2025
·
Deals
www.fiercebiotech.com
License out/inPROTACs
GSK has its pick of partner from Flagship Pioneering's 40-plus portfolio companies.
GSK has picked a novel protein biFlagship Pioneerings biotech as its first collaborators under a $7 billion biobucks deal with Flagship Pioneering.
GSKgship’s Profound Therapeutics and Quotient Therapeutics have signed separate feasibility agreements with the British pharma that center around discovering new targets and therapeutic approaches for respiratory and liver diseases, according to a Nov. 20 release.
These are the first company-specific Quotient Therapeuticsagship and GSK’s partnership inked back in July 2024. The two partners put down a combined $150 million toward respiratory- and immunology-focurespiratory and liver diseasesal of Flagship’s 40-plus portfolio biotechs. The end goal of the deal is to identify up to 10 new medicines that GSK will have an exclusive option to take forward for further clinical development.
For each program GSK picks up, Flagship and its companieFlagshipceiveGSK to $720 million in upfront, development and commercial milestones from GSK, plus preclinical funding and royalties on sales. That equates to a possible $7 billion-pFlagship value hanging on the line.GSK
For ProFound’s piGSK, the bioteFlagshipuse its protein detection platform to identify and validate new proteins and drug targets within the expaGSKd human proteome.
The ProFoundation encompasses two different pacts that will include finding novel proteins with significant genetic ties to chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).
Meanwhile, Quotient will leverage its somatic genomics platform in hopes of unlocking new treatments by studying genetic divchronic obstructive pulmonary disease (COPD)idiopathic pulmonary fibrosis (IPF)
In QuotientQuotient GSK has penned three separate agreements that revolve around finding disease-causing drug targets for COPD, IPF and metabolic dysfunction-associated steatohepatitis.
If QuotientPharma deGSKes to move forward with an agreement, the respective biotech will advance its program through key pCOPDinIPFl devmetabolic dysfunction-associated steatohepatitise option to take the candidate into clinical testing.
NotablyBig Pharma and Quotient are two biotechs involved in another Flagship-pharma collaboration. In 2023, Pfizer set the blueprint for the VC-pharma pacts, GSKing to build a new pipeline of 10 programs and offering Flagship and its biotechs the chance to make up to $700 million in biobucks for each successful drug.
Pfizer haProfound QuotQuotienthelp discover new targets for two progFlagshipcardiovascular and renal diseasePfizerle asking Profound to find proteins and determine whether they can be used for new obesity therapeuticsFlagship
Pfizerip currently has more than 40 companies under its wing, including Genecardiovascular and renal diseases Tessera TherapProfoundnd Valo Health.obesity
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!